CA
PBE icon

Cetera Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Cetera Advisors’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$328K Buy
+5,066
New +$330K ﹤0.01% 1879

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
CW
CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return
EH
Equitable Holdings New York $15.5B AUM 19.09% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Cetera Advisors's PBE Position: Q1 2024 in Review

Cetera Advisors opened a new position in Invesco Biotechnology & Genome ETF (PBE) in Q1 2024: 5,066 shares worth $328K. The stake represents ﹤0.01% of the portfolio and ranks #1879 among its holdings.

102 funds tracked by Wall St. Rank hold PBE as of Q1 2024.

  • Cetera Advisors held 5,066 shares of Invesco Biotechnology & Genome ETF worth $328K as of Q1 2024.
  • Invesco Biotechnology & Genome ETF was a new Cetera Advisors position in Q1 2024.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Cetera Advisors's portfolio in Q1 2024, its #1879 holding.
  • 102 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.